Ministry of Health and Welfare Revises Drug Pricing System for the First Time in 13 Years
Generic Price Calculation Rate to Be Lowered from 53.55% to the 40% Range of the Original
Flexible Drug Price Contracts to Improve Access to Rare Disease Treat

The government has initiated a sweeping overhaul of the drug pricing system to lower the prices of generic drugs, which have been criticized for being more expensive than international standards. The aim is to improve patient access to treatment and reduce the financial burden of medication, while also driving structural reform in the domestic pharmaceutical industry and promoting new drug development. However, pharmaceutical companies with a high proportion of generic drug sales are strongly opposing the move, arguing that reduced sales will in fact shrink their research and development (R&D) investment.


Lowering Generic Drug Prices and Fostering Innovative New Drugs... Pharmaceutical Industry Warns of Inevitable R&D Setbacks View original image

Flexible Drug Price Contracts to Improve Access to Rare Disease Treatments

According to the “Drug Pricing System Improvement Plan” reported by the Ministry of Health and Welfare to the Health Insurance Policy Deliberation Committee on November 28, the government plans to drastically simplify the reimbursement eligibility assessment and negotiation procedures for rare disease treatments starting next year. The maximum reimbursement listing period, which can currently take up to 240 days, will be shortened to within 100 days.


To ensure that innovative pharmaceuticals are introduced quickly in Korea and remain competitive in overseas markets, the government will also implement a new system?tentatively called the “flexible drug price contract”?that allows the National Health Insurance Service and pharmaceutical companies to sign separate contracts. Until now, the relatively low drug prices in Korea have led some multinational pharmaceutical companies to hesitate in launching new drugs in the Korean market. As this phenomenon of “Korean passing” for new drugs has continued, the existing “single price system” has been criticized for failing to reflect the appropriate value of pharmaceuticals.


The government plans to significantly expand the scope of the flexible drug price contract starting in the first quarter of next year, covering newly listed new drugs, off-patent originals, new drugs whose risk-sharing reimbursement has ended, and biosimilars.


Measures will also be introduced to stabilize the supply of essential medicines. The government will expand the scope of price premiums for national essential medicines and guarantee preferential periods. For “withdrawal prevention medicines,” which have been operated without improvement since their introduction in 2000, the government will raise designation standards and introduce new policy premiums, further refining the pricing system. These changes are scheduled to take effect in the second half of next year.


Lowering Generic Drug Prices and Fostering Innovative New Drugs... Pharmaceutical Industry Warns of Inevitable R&D Setbacks View original image

Lowering Generic Prices and Adding Premiums for Innovation

In addition, the government will lower the price calculation rate for generics and off-patent drugs from the current 53.55% of the original drug price to the 40% range. This will apply to products that have maintained their initial calculated price for over a decade since the 2012 drug price reform.


Currently, the price of generic drugs is set at 53.55% of the original, with incremental 15% reductions based on evaluations of innovation and supply stability. The revised plan maintains this framework but further subdivides the evaluation criteria.


To prevent the indiscriminate increase of low-quality generics, the government will strengthen the stepwise price reduction: starting from the 11th generic with the same ingredient, the price will be cut by an additional 5 percentage points for each subsequent product. If more than 10 generics are listed when the first generic is launched, after one year, all products will be adjusted to the price of the 11th generic, tightening the management of multiple product listings.


The government plans to finalize these policy tasks after gathering further feedback and will swiftly revise relevant regulations to implement them sequentially from the first quarter of next year.


However, the pharmaceutical industry is opposing these drug pricing reforms, arguing that a significant portion of their revenue could be affected. The Emergency Response Committee for Drug Pricing Reform, which includes the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, stated, “If the price calculation criteria are drastically lowered as proposed, the core resources for R&D investment and employment will shrink, leading to delays in new drug development, reduced facility investment, and a decline in global competitiveness. In particular, if drug prices fall to cost levels, companies will have no choice but to cut back on the production of low-priced essential medicines first.”



The committee added, “Drug price incentives for companies with high R&D investment ratios and those contributing to supply stability must be further strengthened to ensure real effectiveness in the field. The government should secure the effectiveness of the system based on rational feedback from the industry and thorough impact analysis before finalizing the improvement plan.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing